• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Incidental Prostate Cancer (cT1a-cT1b) Is a Relevant Clinical and Research Entity and Should Be Fully Discussed in the International Prostate Cancer Guidelines.

作者信息

Capitanio Umberto, Autorino Riccardo, Bandini Marco, Briganti Alberto, Cheng Liang, Cooperberg Matthew R, Dehò Federico, Gallina Andrea, Klotz Laurence, Lane Brian, Montironi Rodolfo, Salonia Andrea, Stief Christian, Tombal Bertrand, Montorsi Francesco

机构信息

Unit of Urology, IRCCS Ospedale San Raffaele, Milan, Italy; Division of Experimental Oncology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy.

Division of Urology, VCU Health, Richmond, VA, USA.

出版信息

Eur Urol Oncol. 2021 Apr 1. doi: 10.1016/j.euo.2021.03.005.

DOI:10.1016/j.euo.2021.03.005
PMID:33814342
Abstract
摘要

相似文献

1
Incidental Prostate Cancer (cT1a-cT1b) Is a Relevant Clinical and Research Entity and Should Be Fully Discussed in the International Prostate Cancer Guidelines.偶发性前列腺癌（cT1a-cT1b）是一个相关的临床和研究实体，应在国际前列腺癌指南中进行充分讨论。
Eur Urol Oncol. 2021 Apr 1. doi: 10.1016/j.euo.2021.03.005.
2
Differential efficacy of ablation therapy versus partial nephrectomy between clinical T1a and T1b renal tumors: A systematic review and meta-analysis.临床 T1a 和 T1b 期肾肿瘤消融治疗与部分肾切除术疗效的差异：系统评价和荟萃分析。
Urol Oncol. 2022 Jul;40(7):315-330. doi: 10.1016/j.urolonc.2022.04.002. Epub 2022 May 11.
3
Contemporary validation of cT1a vs. cT1b substaging of incidental prostate cancer.当代验证偶然前列腺癌的 cT1a 与 cT1b 亚分期。
World J Urol. 2024 Apr 28;42(1):269. doi: 10.1007/s00345-024-04940-3.
4
Partial Nephrectomy Versus Radical Nephrectomy for Clinical T1b and T2 Renal Tumors: A Systematic Review and Meta-analysis of Comparative Studies.部分肾切除术与根治性肾切除术治疗 T1b 和 T2 期临床肾肿瘤的比较：系统评价和荟萃分析。
Eur Urol. 2017 Apr;71(4):606-617. doi: 10.1016/j.eururo.2016.08.060. Epub 2016 Sep 7.
5
EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.EAU 前列腺癌指南。第二部分：晚期、复发性和去势抵抗性前列腺癌的治疗。
Eur Urol. 2014 Feb;65(2):467-79. doi: 10.1016/j.eururo.2013.11.002. Epub 2013 Nov 12.
6
[Guidelines for the prevention and management of bronchial asthma (2024 edition)].[支气管哮喘防治指南（2024年版）]
Zhonghua Jie He He Hu Xi Za Zhi. 2025 Mar 12;48(3):208-248. doi: 10.3760/cma.j.cn112147-20241013-00601.
7
Prescription of Controlled Substances: Benefits and Risks管制药品的处方：益处与风险
8
MRI software and cognitive fusion biopsies in people with suspected prostate cancer: a systematic review, network meta-analysis and cost-effectiveness analysis.磁共振成像软件联合认知融合活检用于疑似前列腺癌患者：系统评价、网络荟萃分析和成本效果分析。
Health Technol Assess. 2024 Oct;28(61):1-310. doi: 10.3310/PLFG4210.
9
EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update.欧洲癌症研究与治疗组织（EORTC）癌症贫血患者促红细胞生成蛋白使用指南：2006年更新版
Eur J Cancer. 2007 Jan;43(2):258-70. doi: 10.1016/j.ejca.2006.10.014. Epub 2006 Dec 19.
10
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer.拓扑替康治疗卵巢癌的临床有效性和成本效益的快速系统评价。
Health Technol Assess. 2001;5(28):1-110. doi: 10.3310/hta5280.

引用本文的文献

1
Optimal PSA density threshold for prostate biopsy in benign prostatic obstruction patients with elevated PSA levels but negative MRI findings.前列腺特异抗原（PSA）水平升高但磁共振成像（MRI）结果为阴性的良性前列腺梗阻患者前列腺穿刺活检的最佳PSA密度阈值
BMC Urol. 2025 Mar 3;25(1):42. doi: 10.1186/s12894-025-01719-5.
2
Oncologic Outcomes of Incidental Versus Biopsy-diagnosed Grade Group 1 Prostate Cancer: A Multi-institutional Study.偶然发现与活检确诊的1级前列腺癌的肿瘤学结局：一项多机构研究
Eur Urol Open Sci. 2024 Aug 20;68:10-17. doi: 10.1016/j.euros.2024.08.004. eCollection 2024 Oct.
3
Return on investment in science: twenty years of European Commission funded research in Alzheimer's dementia, breast cancer and prostate cancer.
科学领域的投资回报：欧盟委员会资助的20年阿尔茨海默病痴呆症、乳腺癌和前列腺癌研究
Cost Eff Resour Alloc. 2024 Jun 16;22(1):51. doi: 10.1186/s12962-024-00540-5.
4
Benign prostatic hyperplasia during active surveillance for prostate cancer: is it time to define management strategies?前列腺癌主动监测期间的良性前列腺增生：是时候定义管理策略了吗？
Prostate Cancer Prostatic Dis. 2024 Apr 29. doi: 10.1038/s41391-024-00837-9.
5
Incidental Prostate Cancer in Patients Treated for Benign Prostatic Hyperplasia: Analysis from a Contemporary National Dataset.良性前列腺增生患者中的偶发性前列腺癌：基于当代全国数据集的分析
Diagnostics (Basel). 2024 Mar 23;14(7):677. doi: 10.3390/diagnostics14070677.
6
Incidence and associated factors for incidental prostate cancer among patients who underwent surgery for benign prostatic hyperplasia: first report from Somalia.在接受良性前列腺增生手术的患者中偶然发现前列腺癌的发病率及相关因素：来自索马里的首次报告。
J Cancer Res Clin Oncol. 2023 Jul;149(7):4041-4046. doi: 10.1007/s00432-022-04319-0. Epub 2022 Aug 29.